Related Experiment Videos
Clinical neurotransplantation: core assessment protocol rather than sham surgery as control
1Graduate School Neurosciences Amsterdam, Netherlands Institute for Brain Research, Amsterdam, The Netherlands. g.boer@nih.knaw.nl
Brain Research Bulletin
|October 10, 2002
Summary
Neural grafting for brain diseases, including Parkinson's, is deemed unsuitable for experimental trials due to irreversibility and lack of optimization. Ethical concerns and the need for standardized assessment protocols (CAPs) are highlighted.
Area of Science:
- Neuroscience
- Neurosurgery
- Clinical Trials
Background:
- Restorative brain surgery via neurotransplantation was explored for Parkinson's disease.
- Clinical trials showed varying symptomatic relief, prompting calls for placebo-controlled studies.
Purpose of the Study:
- To discuss and reject the approach of experimental neurotransplantation in brain diseases.
- To highlight the unsuitability of irreversible neural grafting for experimental drug-like studies.
Main Methods:
- Review of existing neurotransplantation research and clinical trial outcomes.
- Ethical considerations regarding informed consent, therapeutic misconception, and risk/benefit ratios.
- Proposal for disease-dedicated core assessment protocols (CAPs) for quantitative evaluation.
Main Results:
- Neural grafting is irreversible and not ideal for experimental approaches.
- Current techniques are not optimized for large-scale Parkinson's disease studies.
- Previous negative results suggest placebo effects are unlikely.
Conclusions:
- Experimental neurotransplantation in brain diseases is rejected.
- Ethical considerations and the need for unbiased study designs are paramount.
- Development of standardized CAPs is recommended for future research and comparisons.